Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chembio Diagnostics (CEMI)

Chembio Diagnostics (CEMI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Chembio Diagnostics 3661 HORSEBLOCK RD MEDFORD NY 11763 USA

https://chembio.com P: 631-924-1135 F: 631-924-2065

Description:

CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.

Key Statistics

Overview:

Market Capitalization, $K 16,710
Enterprise Value, $K 17,120
Shares Outstanding, K 36,726
Annual Sales, $ 49,520 K
Annual Net Income, $ -23,290 K
Last Quarter Sales, $ 10,340 K
Last Quarter Net Income, $ -860 K
60-Month Beta 1.85
% of Insider Shareholders 3.30%
% of Institutional Shareholders 8.65%
Float, K 35,514
% Float 96.70%
Short Volume Ratio 0.70

Growth:

1-Year Return -26.73%
3-Year Return -96.42%
5-Year Return -94.42%
5-Year Revenue Growth 106.16%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.21 on 11/03/22
Latest Earnings Date 05/04/23
Earnings Per Share ttm -0.73
EPS Growth vs. Prev Qtr 8.70%
EPS Growth vs. Prev Year 8.70%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 05/30/12

CEMI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -113.57%
Return-on-Assets % -38.22%
Profit Margin % -47.03%
Debt/Equity 0.00
Price/Sales 0.34
Price/Cash Flow N/A
Price/Book 0.94
Book Value/Share 0.48
Interest Coverage -7.28
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar